SEC Form 4	ļ												
FC	ORM 4	D STATES S	SECURITIES Washing		OMB APPROVAL								
Section 16.	ox if no longer subject Form 4 or Form 5 nay continue. <i>See</i> (b).	to STA	Filed pursua	F CHANGES ant to Section 16(a) action 30(h) of the Ir	Estin	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5							
1. Name and Address of Reporting Person* Froimson Mark				uer Name <b>and</b> Ticke <u>ra BioScienc</u> e			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)	(First)	(Middle)		e of Earliest Transa 4/2023	Officer (give title below)	Other below	(specify )						
C/O PACIRA BIOSCIENCES, INC. 5401 WEST KENNEDY BOULEVARD, SUITE 890 (Street)				mendment, Date of	Original Filed	(Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
TAMPA	FL	33609		Rule 10b5-1(c) Transaction Indication									
(City)	(State)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									
		Table I - No	n-Derivative S	Securities Acq	uired, Disp	oosed of, or Benef	icially	Owned					
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	Disposed Of (D) (Instr. 3, 4 and 5) Securities Beneficia Owned Fe		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying 8. Price of Derivative 1. Title of Derivative 3. Transaction Date 3A. Deemed Execution Date 9. Number of 10. Ownership 5. Number 4. Transaction Code (Instr. 8) 2. Conversion of derivative Security (Instr. 3) or Exercise Price of if any (Month/Day/Year) Derivative Securities Security (Instr. 5) Securities Beneficially Form: Direct (D) (Month/Day/Year) Acquired (A) or Disposed Derivative Derivative Security (Instr. 3 and 4) Owned Following or Indirect (I) (Instr. 4) Security Reported of (D) Transaction(s)

					(Instr. 3, 4 and 5)							(Instr. 4)		
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$38.74	06/14/2023	A		12,925		06/14/2024	06/14/2033	Common Stock	12,925	\$0.00	12,925	D	

Code V

Α

Explanation of Responses:

1. Represents restricted stock units that vest on June 3, 2024, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

## **Remarks:**

Common Stock

<u>/s/ Kristen Williams, Attorney-</u> <u>in-Fact</u> <u>06/16/2023</u>

(A) or (D)

Α

Price

\$0.00

Amount

1,775<sup>(1)</sup>

Transaction(s)

(Instr. 3 and 4)

7,843

D

11. Nature

of Indirect Beneficial Ownership

(Instr. 4)

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

06/14/2023

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.